Sargramostim clinical trials
Also written BAY86-5326 and DRG-0012.
How each study uses sargramostim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sargramostim studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 Mar 1991 · LEUKINE · BLA 103362 (FDA, Drugs@FDA)
- European Union
- 21 Aug 2025 · Imreplys · EMEA/H/C/006411 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
138 studies that test it; most in 2004 (13)
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1995 | 3 |
| 1996 | 3 |
| 1997 | 4 |
| 1998 | 4 |
| 1999 | 7 |
| 2000 | 11 |
| 2001 | 8 |
| 2002 | 7 |
| 2003 | 7 |
| 2004 | 13 |
| 2005 | 5 |
| 2006 | 11 |
| 2007 | 5 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 3 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 117
National Cancer Institute (NCI) (13) · Genzyme, a Sanofi Company (8) · University of Nebraska (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Children's Oncology Group (5) · University of Washington (4) · Partner Therapeutics, Inc. (4) · University of Colorado, Denver (4)
Often tested with
Tested in the same studies.
Cyclophosphamide (9) · Rituximab (8) · Etoposide (8) · Doxorubicin (6) · Filgrastim (6) · Vincristine (4) · Aldesleukin (4) · Carboplatin (4)
Related medicines
As reviewed, each with the page that says it.
- A recombinant medicine of Granulocyte-Macrophage Colony-Stimulating Factor source
- One of Immunologic Factors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test sargramostim.
- Nov 2026Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's DiseasePhase 2 · University of Colorado, Denver
- Dec 2026GM-CSF With Post-Transplant CyclophosphamidePhase 2 · Northside Hospital, Inc.
Studies
Open first, then newest update. How each study uses sargramostim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 142
- GM-CSF With Post-Transplant CyclophosphamideRecruitingPhase 2Northside Hospital, Inc.NCT04237623Written as Sargramostim
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With NeuroblastomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06528496Written as Sargramostim
- Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's DiseaseRecruitingPhase 2University of Colorado, DenverNCT04902703Written as Sargramostim
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00669734Written as Sargramostim
- Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By SurgeryCompletedPhase 3National Cancer Institute (NCI)NCT01989572Written as Sargramostim
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedPhase 2National Cancer Institute (NCI)NCT03786783Written as Sargramostim
- GM-CSF to Decrease ICU Acquired InfectionsCompletedPhase 3Hospices Civils de LyonNCT02361528Written as Sargramostim: Leukine (Genzyme USA)
- Biomarker Assessments of Leukine During Treatment of Parkinson's DiseaseCompletedPhase 1University of NebraskaNCT03790670Written as sargramostim
- Biomarker Validation Following Sargramostim Treatment in Parkinson's DiseaseCompletedPhase 1University of NebraskaNCT05677633Written as Sargramostim
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruitingPhase 2Children's Oncology GroupNCT04385277Written as Sargramostim
- Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian CancerCompletedPhase 1University of WashingtonNCT00436254Written as sargramostim
- Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down SyndromeWithdrawnPhase 2University of Colorado, DenverNCT05482334Written as Sargramostim for Injection
- A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate CancerCompletedPhase 1/2Ultimovacs ASANCT01784913Written as UV1 synthetic peptide vaccine and GM-CSF
- A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.CompletedPhase 1/2Ultimovacs ASANCT01789099Written as UV1 synthetic peptide vaccine and GM-CSF
- A Phase II/III Study of SargramostimCompletedPhase 2/3NobelpharmaNCT04642950Written as Sargramostim
- Inhaled GM-CSF Therapy of Autoimmune PAPCompletedPhase 2Fondazione IRCCS Policlinico San Matteo di PaviaNCT00901511Written as Sargramostim
- Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedPhase 2National Cancer Institute (NCI)NCT00019097Written as sargramostim
- Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's LymphomaCompletedPhase 2University of NebraskaNCT00004198Written as sargramostim
- TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and SurgeryStatus unknownPhase 2Academic and Community Cancer Research UnitedNCT04197687Written as Sargramostim
- Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent OsteosarcomaCompletedPhase 2National Cancer Institute (NCI)NCT02484443Written as Sargramostim
See all 142 studies that test sargramostim →
Given beside what is tested · 88 — sargramostim is usual care or a partner of the new treatment
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingPhase 1/2National Cancer Institute (NCI)NCT07437963Written as Sargramostim
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasNot yet recruitingPhase 2Roswell Park Cancer InstituteNCT06202066Written as Sargramostim
- Testing the SurVaxM Vaccine for Lung Cancer PreventionNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07169617Written as Sargramostim
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingPhase 3Children's Oncology GroupNCT03126916Written as Sargramostim
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsRecruitingPhase 1/2Mayo ClinicNCT05269381Written as Sargramostim
- A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaRecruitingPhase 2St. Jude Children's Research HospitalNCT07085338Written as Sargramostim
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT07078604Written as Sargramostim
- A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung CancerRecruitingPhase 2University of WashingtonNCT05242965Written as Sargramostim
- Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory NeuroblastomaRecruitingPhase 1Steven DuBois, MDNCT07027748Written as Sargramostim granulocyte-macrophage colony stimulating factor
- Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung CancerRecruitingPhase 2Vestre Viken Hospital TrustNCT05344209Written as Sagramostim
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01134614Written as Sargramostim
- A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT02339571Written as Sargramostim
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingPhase 2Roswell Park Cancer InstituteNCT02455557Written as Sargramostim
- NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabActive, not recruitingPhase 1/2Nationwide Children's HospitalNCT04211675Written as Sargramostim
- STEMVAC in Patients With Early Stage Triple Negative Breast CancerActive, not recruitingPhase 2University of WashingtonNCT05455658Written as Sargramostim
- Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerActive, not recruitingPhase 2Aston Sci. Inc.NCT05771584Written as rhuGM-CSF
- Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerActive, not recruitingPhase 2Academic and Community Cancer Research UnitedNCT03012100Written as Sargramostim
- A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage AdenocarcinomaSuspendedPhase 1/2University of California, DavisNCT05101356Written as Sargramostim
- Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedPhase 3National Cancer Institute (NCI)NCT01041638Written as Sargramostim
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingPhase 1Roswell Park Cancer InstituteNCT02334865Written as Sargramostim
Showing 20 of 88.
As the comparator · 2 — what is tested is compared with sargramostim
- Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT02636582Written as Sargramostim
- Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer RecurrenceCompletedPhase 3Galena Biopharma, Inc.NCT01479244Written as Leukine® (sargramostim, GM-CSF) and water for injection
Codes
What other systems call sargramostim · ClinicalTrials.gg INT003728
- MeSH (NLM) C081222sargramostimConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5TAA004E22SARGRAMOSTIMConfirmed FDA, NLM, Wikidata
- RxNorm 69634Confirmed FDA, Wikidata
- Wikidata Q3950557sargramostimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1492SargramostimOne source FDA
- DrugBank DB00020One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C081222 | sargramostim | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5TAA004E22 | SARGRAMOSTIM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 69634 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3950557 | sargramostim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1492 | Sargramostim | One source FDA |
| DrugBank | DB00020 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.